Patents Examined by Maria Leavitt
  • Patent number: 9777061
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: October 3, 2017
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hilmar Erhard Ebersbach, Thomas Huber, Julia Jascur, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
  • Patent number: 9771624
    Abstract: The multiple embodiments described herein comprise the genome of a probiotic Bifidobacterium longum bifidobacteria strain and genes encoded by the genome. Various novel Bifidobacterium longum are described.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: September 26, 2017
    Assignee: The Procter & Gamble Company
    Inventors: Douwe Van Sinderen, Jun Xu, Wenzhu (Steven) Zhao, Raymond A. Grant, Song Yuli, Charles Bascom, Duane Larry Charbonneau, Liam O'Mahony
  • Patent number: 9745561
    Abstract: The genetic basis for severe combined immunodeficiency disease (SCID) in pigs is described. In addition, tests for detecting pigs that are carriers for SCID or pigs with SCID are also described. Further, methods for producing pigs or herds of pigs with SCID are also described. Further, methods and compositions for treating, ameilioraing, inhibiting or correcting SCID are provided.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: August 29, 2017
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Jack C. M. Dekkers, Christopher K. Tuggle, Emily H. Waide, Jason W. Ross, N. Matthew Ellinwood, Martine Schroyen
  • Patent number: 9745589
    Abstract: This invention is based, at least in part, on the discovery that Shn2 and Shn3 play an important role in skeletal remodeling and skeletal patterning. Accordingly, the present invention provides methods for identifying medulators of Shn2 activity and methods for modulating bone formation and mineralization and Shn2-associated disorders using agents that modulate Shn2 expression and/or activity, in addition to methods for modulating Shn2 and Shn3.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: August 29, 2017
    Assignee: Cornell University
    Inventors: Laurie H. Glimcher, Dallas C. Jones, Marc Wein
  • Patent number: 9746471
    Abstract: The present invention relates to the identification of p53 biomarker profiles that predict response in patients with hyperproliferative disease such as cancer to a therapy, and their use in methods of treating such patients with an anti-hyperproliferative disease gene therapy.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: August 29, 2017
    Assignee: MULTIVIR INC.
    Inventors: Robert E. Sobol, Kerstin Menander
  • Patent number: 9737569
    Abstract: ECM based compositions including amniotic membrane and methods for employing same to treat cardiovascular disorders.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: August 22, 2017
    Assignee: CorMatrix Cardiovascular, Inc.
    Inventor: Robert G Matheny
  • Patent number: 9731014
    Abstract: Methods for treating inflammation are disclosed, such as for treating ocular inflammation. In some embodiments, the ocular inflammation is inflammation of an ocular surface, such as keratitis. The methods include administering to a subject with inflammation a therapeutically effective amount of SLURP1, or a nucleic acid encoding SLURP1, thereby treating the inflammation.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: August 15, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Shivalingappa Kottur Swamynathan, Sudha Swamynathan, Kristine-Ann Gallegos Buela, Robert Lee Hendricks
  • Patent number: 9714415
    Abstract: A method for stem or progenitor cell culture. More precisely, the invention relates to a method for cell culture using one or more I?I (inter-alpha trypsin inhibitor or Inter-alpha inhibitor) protein(s) or part(s) thereof as a component in a cell culture media or a coating on a cell culture surface material. Furthermore the invention relates to a cell culture media and a cell culture coating/matrix provided with one or more I?I proteins(s) or part(s) thereof.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: July 25, 2017
    Assignee: GE Healthcare Bio-Sciences AB
    Inventors: Sara Pijuan Galito, Christoffer Tamm, Cecilia Anneren
  • Patent number: 9714280
    Abstract: Disclosed herein are genetically modified cells expressing HLA-G (e.g., cell surface HLA-G) persistently, and nucleic acid compositions useful for generating such genetically modified cells. Also disclosed are cell therapy methods that utilize genetically modified cells that express HLA-G persistently. The HLA-G genetic modifications described herein provide the cells with characteristics of reduced immunogenicity and/or improved immunosuppression, such that these cells have the promise of being universal or improved donor cells for transplants, cellular and tissue regeneration or reconstruction, and other therapies.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: July 25, 2017
    Assignee: ESCAPE THERAPEUTICS, INC.
    Inventor: Basil M. Hantash
  • Patent number: 9701983
    Abstract: Reagents and methods are provided that allow for an improved expression of a recombinant protein in an insect, More specifically, the introduction of recombinant DNA elements into an insect larva allows for the increased expression of a recombinant protein, an improvement of the correct folding of said protein and an increase in the survival rate after infection of the insect These recombinant DNA elements can be introduced, for example, into insect larvae via a recombinant baculovirus, which has incorporated said elements. The recombinant DNA elements include nucleic acids encoding transcriptional regulators, such as IE-0 and IE-1, transcriptional, enhancer elements, such as the homologous region (hr) and promoters.
    Type: Grant
    Filed: June 12, 2012
    Date of Patent: July 11, 2017
    Assignee: ALTERNATIVE GENE EXPRESSION S.L.
    Inventors: Silvia Gomez Sebastian, Javier López Vidal, José Angel Martinez Escribano
  • Patent number: 9688973
    Abstract: The present invention relates to isolated polypeptides having alpha-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: June 27, 2017
    Assignee: NOVOZYMES, INC.
    Inventors: Suzanne Otani, Haiyan Ge, Paul Harris, Debbie Yaver, Alexander Blinkovsky
  • Patent number: 9686970
    Abstract: Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: June 27, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Karolina A. Meagher, Andrew J. Murphy
  • Patent number: 9670281
    Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: June 6, 2017
    Assignee: The Regents of the University of California
    Inventors: Wendell A. Lim, Leonardo Morsut, Kole T. Roybal
  • Patent number: 9668499
    Abstract: The present invention is directed to isolated microorganisms as well as strains and mutants thereof, biomasses, microbial oils, compositions, and cultures; methods of producing the microbial oils, biomasses, and mutants; and methods of using the isolated microorganisms, biomasses, and microbial oils.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: June 6, 2017
    Assignee: DSM IP Assets B.V.
    Inventors: Kirk E. Apt, Paul Warren Behrens, Jon Milton Hansen, Joseph W. Pfeifer, III, Tracey Lynn Stahl, Ross Zirkle
  • Patent number: 9655927
    Abstract: Disclosed herein are cell preparations useful for modulating various peripheral immune functions, methods for making said cell preparations, and methods for their use.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: May 23, 2017
    Assignee: SanBio, Inc.
    Inventors: Mo Dao, Casey C. Case
  • Patent number: 9657060
    Abstract: The invention provides natural IgM antibody inhibitors that may be used to treat various inflammatory diseases or disorders.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: May 23, 2017
    Assignees: Children's Medical Center Corporation, President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.
    Inventors: Michael C. Carroll, Francis D. Moore, Herbert B. Hechtman
  • Patent number: 9622955
    Abstract: The present application relates to use of a Midkine family protein for growing hair on a mammal, or in the manufacture of a medicament for growing hair on a mammal, especially for treatment or prevention of different forms of alopecia.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: April 18, 2017
    Assignee: Advangen International Pty Ltd
    Inventors: Sadatoshi Sakuma, Maria Halasz, Darren Jones
  • Patent number: 9615550
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 11, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens
  • Patent number: 9611480
    Abstract: The invention relates to the fields of molecular biology and medicine, more specifically to treatment and prevention of heart disease. The invention provides alternative methods for counteracting, diminishing, treating, delaying and/or preventing heart disease.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: April 4, 2017
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Leon Johannes De Windt, Hamid El Azzouzi
  • Patent number: 9591835
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: March 14, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens, Yingzi Xue